- Home
- ALMU vs SKYE Comparison
ALMU vs SKYE Comparison
Compare ALMU & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMU
- SKYE
- Stock Information
- Founded
- ALMU 2019
- SKYE 2012
- Country
- ALMU United States
- SKYE United States
- Employees
- ALMU N/A
- SKYE N/A
- Industry
- ALMU Semiconductors
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ALMU Technology
- SKYE Health Care
- Exchange
- ALMU Nasdaq
- SKYE Nasdaq
- Market Cap
- ALMU 76.5M
- SKYE 80.7M
- IPO Year
- ALMU N/A
- SKYE N/A
- Fundamental
- Price
- ALMU $8.34
- SKYE $1.82
- Analyst Decision
- ALMU
- SKYE Buy
- Analyst Count
- ALMU 0
- SKYE 6
- Target Price
- ALMU N/A
- SKYE $16.60
- AVG Volume (30 Days)
- ALMU 88.2K
- SKYE 1.7M
- Earning Date
- ALMU 05-09-2025
- SKYE 05-09-2025
- Dividend Yield
- ALMU N/A
- SKYE N/A
- EPS Growth
- ALMU N/A
- SKYE N/A
- EPS
- ALMU N/A
- SKYE N/A
- Revenue
- ALMU $2,716,416.00
- SKYE N/A
- Revenue This Year
- ALMU N/A
- SKYE N/A
- Revenue Next Year
- ALMU N/A
- SKYE N/A
- P/E Ratio
- ALMU N/A
- SKYE N/A
- Revenue Growth
- ALMU 455.81
- SKYE N/A
- 52 Week Low
- ALMU $2.50
- SKYE $1.14
- 52 Week High
- ALMU $18.00
- SKYE $13.51
- Technical
- Relative Strength Index (RSI)
- ALMU N/A
- SKYE 51.69
- Support Level
- ALMU N/A
- SKYE $1.36
- Resistance Level
- ALMU N/A
- SKYE $3.73
- Average True Range (ATR)
- ALMU 0.00
- SKYE 0.35
- MACD
- ALMU 0.00
- SKYE 0.09
- Stochastic Oscillator
- ALMU 0.00
- SKYE 26.29
About ALMU Aeluma Inc. Common Stock
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.